GSK, hep B, Inmatics cancer therapy, Mark Cuban: The Readout

Elaine’s tales discover the growth in new weight problems therapies, new drug fee fashions, the methods corporations are affected by FDA adjustments, and the rising psychedelics drug sector. She co-writes The Readout e-newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You possibly can attain Elaine on Sign at elaineywchen.70.

Andrew covers the biopharma business, scientific analysis, and public well being throughout the continent. You possibly can attain Andrew confidentially on Sign at drewqjoseph.71.

Need to keep on high of the science and politics driving biotech at present? Join to get our biotech e-newsletter in your inbox.

Good morning. Final spring, my colleague acquired an intriguing electronic mail from Mark Cuban. From there, a narrative was born. Learn on for extra.

The necessity-to-know this morning

Roivant and its subsidiary Priovant introduced optimistic outcomes throughout two Section 3 research of their drug Lisraya in non-infectious uveitis, an inflammatory eye illness that may result in imaginative and prescient loss. Lisraya was just lately authorised to deal with dermatomyositis, one other inflammatory situation. Roivant stated it should search an expanded FDA approval for Lisraya within the first half of 2027. 

Cuban’s Price Plus Medication is entering into uncommon illness

Mark Cuban’s Price Plus Medication, the web pharmacy that goals to decrease drug prices by bypassing middlemen, has principally been promoting generic medication. However the firm is entering into a way more difficult area — experimental uncommon illness therapies.